A double blind, randomised, placebo-controlled, crossover study assessing the use of XEN D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy.

Trial Profile

A double blind, randomised, placebo-controlled, crossover study assessing the use of XEN D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Aug 2015

At a glance

  • Drugs XEN D0103 (Primary)
  • Indications Paroxysmal atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms XAPAF
  • Sponsors Xention
  • Most Recent Events

    • 01 Aug 2015 Status changed from recruiting to completed, as reported by European Clinical Trials Database.
    • 10 Jun 2014 New source identified and integrated (European Clinical Trials Database: EudraCT2013-004456-38)
    • 21 Apr 2014 According to the European Clinical Trials Database record, status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top